Sort   by:  
 Page size 
UnknownRetFM-J, an ImageJ-based module for automated counting and quantifying features of nuclei in retinal whole-mounts.
Not available
S-EPMC4753132 | biostudies-literature
UnknownPersistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.
Not available
S-EPMC3138635 | biostudies-literature
UnknownQuantitative measurement of retinal ganglion cell populations via histology-based random forest classification.
Not available
S-EPMC4841761 | biostudies-literature
UnknownCabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.
Not available
S-EPMC4383838 | biostudies-literature
UnknownRadiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.
Not available
S-EPMC4881370 | biostudies-literature
UnknownEffects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone.
Not available
S-EPMC3295561 | biostudies-literature
UnknownRandomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Not available
S-EPMC4962710 | biostudies-literature
UnknownIntense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.
Not available
S-EPMC4226804 | biostudies-literature
UnknownDose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Not available
S-EPMC3816958 | biostudies-literature
UnknownTrial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
Not available
S-EPMC4872347 | biostudies-literature
Sort   by:  
 Page size